<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on July 28, 2020</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT04029012</url>
  </required_header>
  <id_info>
    <org_study_id>Penthrox in Rezūm BPH - Pilot</org_study_id>
    <nct_id>NCT04029012</nct_id>
  </id_info>
  <brief_title>Penthrox in Rezūm BPH - Pilot</brief_title>
  <official_title>A Pilot Study to Assess Efficacy and Safety of Methoxyflurane for Pain Control During Convective Thermal Therapy Using Rezūm System in Benign Prostatic Hyperplasia (BPH)</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Dean Elterman</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>Can-Am HIFU Inc.</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
    <is_fda_regulated_drug>No</is_fda_regulated_drug>
    <is_fda_regulated_device>No</is_fda_regulated_device>
    <is_us_export>No</is_us_export>
  </oversight_info>
  <brief_summary>
    <textblock>
      Open-labeled, single-centre study
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Patients who have elected Convective Thermal Therapy using Rezūm System for the management of
      their BPH and fulfilled inclusion and exclusion criteria will sign informed consent form for
      the study. Patient will use Methoxyflurane inhaler (Penthrox™) on top of standard oral
      analgesia including oral lorazepam, oral Percocet® (oxycodone and acetaminophen) or oxycodone
      immediate-release, and intra-urethral lidocaine gel (Xylocaine®). Intravenous propofol will
      be used as rescue analgesia.
    </textblock>
  </detailed_description>
  <overall_status>Not yet recruiting</overall_status>
  <start_date type="Anticipated">September 2019</start_date>
  <completion_date type="Anticipated">December 2019</completion_date>
  <primary_completion_date type="Anticipated">December 2019</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>N/A</allocation>
    <intervention_model>Single Group Assignment</intervention_model>
    <primary_purpose>Prevention</primary_purpose>
    <masking>None (Open Label)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Pain intensity</measure>
    <time_frame>immediately after final injection of Rezūm treatment</time_frame>
    <description>Visual Analog Scale (VAS)</description>
  </primary_outcome>
  <number_of_arms>1</number_of_arms>
  <enrollment type="Anticipated">10</enrollment>
  <condition>Pain</condition>
  <condition>BPH</condition>
  <arm_group>
    <arm_group_label>Penthrox</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>methoxyflurane inhaler (Penthrox)</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Methoxyflurane</intervention_name>
    <description>Methoxyflurane inhaler before Rezum procedure</description>
    <arm_group_label>Penthrox</arm_group_label>
    <other_name>Penthrox</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:

          -  Male subjects of ≥ 18 years of age

          -  Patient who has elected Convective Thermal Therapy using Rezūm System for the
             management of their benign prostatic hyperplasia.

          -  No contra-indication on using Methoxyflurane inhaler (Penthrox™).

          -  Willing and able to accurately complete the required questionnaires.

          -  Willing and able to provide signed and dated informed consent.

        Exclusion Criteria:

          -  Ongoing use of analgesic agents for chronic pain.

          -  Concomitant use of nephrotoxic agents.

          -  INR &gt; 4.

          -  Use of Methoxyflurane inhaler (Penthrox™) within the previous 3 months.

          -  Known allergy to Lorazepam, Percocet/ Oxycodone, or Xylocaine® gel.

          -  Known personal or familial hypersensitivity to Methoxyflurane inhaler (Penthrox™) or
             other halogenated anesthetics.

          -  Clinically significant respiratory depression, cardiovascular instability, renal or
             hepatic impairment.

          -  An altered level of consciousness, due to any cause, including head injury, drugs, or
             alcohol.

          -  Known or genetically susceptible to malignant hyperthermia or a history of severe
             adverse reactions in either patient or relatives.

          -  A history of liver dysfunction after previous Methoxyflurane inhaler (Penthrox™) use
             or other halogenated anesthetics.
      </textblock>
    </criteria>
    <gender>Male</gender>
    <gender_based>Yes</gender_based>
    <gender_description>Patient with BPH</gender_description>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>N/A</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <verification_date>July 2019</verification_date>
  <study_first_submitted>July 19, 2019</study_first_submitted>
  <study_first_submitted_qc>July 22, 2019</study_first_submitted_qc>
  <study_first_posted type="Actual">July 23, 2019</study_first_posted>
  <last_update_submitted>July 22, 2019</last_update_submitted>
  <last_update_submitted_qc>July 22, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">July 23, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Sponsor-Investigator</responsible_party_type>
    <investigator_affiliation>Can-Am HIFU Inc.</investigator_affiliation>
    <investigator_full_name>Dean Elterman</investigator_full_name>
    <investigator_title>Clinician Investigator/ Urologist</investigator_title>
  </responsible_party>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Methoxyflurane</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

